started a clinical study of AZD-4635 in combination with the anti-CD73 antibody oleclumab (MEDI9447) to investigate the safety, tolerability, and antitumor activity of novel combination therapies administered in subjects with advanced non-small cell lung cancer (NSCLC) [NCT03381274]. This evidence concerns the gene NT5E and non-small cell lung carcinoma.